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The in vitro activities of gemifloxacin, ciprofloxacin, ampicillin, doxycycline, gentamicin, and vancomycin
were evaluated against 15 Listeria monocytogenes strains and 205 coryneform bacteria isolated from clinical
samples. The percentages of strains inhibited by gemifloxacin at 0.5 mg/ml were 100% (L. monocytogenes), 93.3%
(Brevibacterium spp.), 90% (Corynebacterium minutissimum), 42.5% (Corynebacterium amycolatum), 20% (Coryne-
bacterium striatum), 12.5% (Corynebacterium jeikeium), and 10% (Corynebacterium urealyticum). One hundred
percent of the L. monocytogenes strains were inhibited by 0.25 mg of gemifloxacin per ml, whereas 0% of the
strains were inhibited by 0.25 mg of ciprofloxacin per ml. Vancomycin at 2 mg/ml inhibited all strains.
Doxycycline and gentamicin at 4 mg/ml inhibited 94 and 49% of the strains, respectively, while ampicillin at 0.5,
2, and 8 mg/ml inhibited 24, 61, and 66% of the strains, respectively. It is concluded that gemifloxacin shows
good in vitro activity against L. monocytogenes and coryneform bacteria except C. jeikeium and C. urealyticum.
Interest in coryneform bacteria has increased in recent
years, especially after the recognition of the medical impor-
tance of some species, including Corynebacterium jeikeium,
Corynebacterium urealyticum, Corynebacterium striatum, Cory-
nebacterium amycolatum, Corynebacterium minutissimum, and
other less frequently isolated organisms (4, 6). There have
been profound changes in the taxonomy of this group of bac-
teria, with the definition of a large number of new species and
the redefinition of organisms already known (4, 6). A good
example of this situation has been the identification of Coryne-
bacterium amycolatum as a very common human pathogen or
colonizer and the finding that this taxon includes practically
all strains previously identified as Corynebacterium xerosis and
a significant number of organisms previously identified as
C. minutissimum, coryneform CDC groups I2 and F2, and, to
a lesser extent, C. striatum (1, 2).
Data about the activities of antimicrobial agents against
coryneform bacteria have been obtained in the past, but data
are available from only a limited number of studies (2, 3, 5, 7,
9–11, 15–17, 19). Several studies have compared different
methodologies for susceptibility testing of coryneform bacte-
ria (8, 20), but specific breakpoints for clinical categorization
of susceptibility testing results are lacking (13, 14). A large
proportion of C. jeikeium, C. urealyticum, and C. amycolatum
strains are multidrug resistant, and only glycopeptides remain
universally active against these species. Some reports suggest
that other species may be susceptible to commonly used anti-
microbial agents, but we lack reliable clinical evidence to sup-
port these in vitro observations. Therefore, it is convenient to
evaluate the activities of new antimicrobial agents against
coryneform bacteria of clinical importance. It is critical that
studies on the activities of antimicrobial agents against coryne-
form bacteria be based on microorganisms identified according
to the taxonomic information obtained over the years in order
to generate information of clinical significance and to allow
comparison of data obtained in different laboratories.
In previous studies we have observed that new quinolones
are more active than older compounds against coryneform
bacteria (10, 11). The objective of the study described here was
to determine the in vitro activity of the new fluoroquinolone
gemifloxacin in comparison with those of other compounds
against different species of coryneform bacteria isolated from
clinical samples.
The following coryneform species (number of isolates) ob-
tained from clinical samples at our laboratory were evaluated:
Listeria monocytogenes (n 5 15), Brevibacterium spp. (n 5 15),
C. amycolatum (n 5 40), C. jeikeium (n 5 40), C. minutissimum
(n 5 20), Corynebacterium pseudodiphteriticum (n 5 10), C.
striatum (n 5 40), and C. urealyticum (n 5 40). All strains
except the C. striatum strains were isolated from January 1991
to January 1999; C. striatum strains were obtained from May
1998 to January 1999. Microorganisms were identified as de-
scribed by Funke et al. (4) with API CORYNE strips and by
additional phenotypic tests when necessary (4, 6). After iden-
tification, the organisms were maintained in tryptic soy broth–
10% glycerol at 280°C. The following reference strains were
also included: C. jeikeium ATCC 43734, C. striatum ATCC
6940, and C. urealyticum ATCC 43042. Staphylococcus aureus
ATCC 29213 and Enterococcus faecalis ATCC 29212 were used
as control strains for susceptibility tests with gemifloxacin
(SmithKline Beecham Pharmaceuticals, Harlow, United King-
dom), ciprofloxacin (Bayer, Leverkusen, Germany), ampicillin
(Sigma, Madrid, Spain), gentamicin (Sigma), doxycycline (Sig-
ma), and vancomycin (Sigma). The concentrations of antimi-
crobial agents ranged from 0.008 to 16 mg/ml (gemifloxacin,
ciprofloxacin, vancomycin) or 0.06 to 128 mg/ml (all other
agents). MICs were determined by a microdilution assay, as
described previously (7, 9–11). Briefly, cation-adjusted Muel-
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ler-Hinton broth (supplemented with 0.5% Tween 80 when
C. jeikeium and C. urealyticum were tested) was used. A sus-
pension with a turbidity equivalent to that of a 0.5 McFarland
standard was prepared in saline by using bacteria grown on
Columbia agar base with 5% sheep blood agar at 35°C for 18
to 24 h. This suspension was further diluted in the same me-
dium used for the microdilution assay to obtain a final inocu-
lum of ca. 5 3 105 CFU/ml. After inoculation the microdilution
plates were incubated at 35°C in air for 24 h (C. jeikeium and
C. urealyticum) or for 18 to 20 h (all other species).
NCCLS has not provided official breakpoints for clinical
categorization of susceptibility testing results for coryneform
bacteria (13, 14). Wise and Andrews (21) have proposed a
breakpoint for susceptibility to gemifloxacin of #0.5 mg/ml.
The percentages of strains inhibited by ciprofloxacin and gemi-
floxacin at 0.5 mg/ml, 1 mg/ml (breakpoint for susceptibility to
ciprofloxacin for staphylococci), or 2 mg/ml (breakpoint for
intermediate susceptibility to ciprofloxacin for staphylococci)
were calculated. The ranges of MICs and the MICs that inhib-
ited 50% (MIC50) and 90% (MIC90) of the strains tested are
shown in Table 1.
All 220 strains tested were inhibited by 2 mg of vancomycin
per ml, in agreement with previous reports (6, 16, 19). All
strains of L. monocytogenes, Brevibacterium spp., C. amycola-
tum, C. pseudodiphteriticum, and C. jeikeium, 80% of C. stria-
tum strains, 90% of C. urealyticum strains, and 95% of C. mi-
nutissimum strains were inhibited by 4 mg of doxycycline per ml
(data not shown). Although tetracycline was not tested in the
present study, other reports have indicated that doxycycline is
more active than tetracycline against coryneform bacteria (6,
19).
All strains of L. monocytogenes were inhibited by 0.25 mg of
gemifloxacin per ml and 2 mg of ciprofloxacin per ml; the MICs
of gemifloxacin were four to eight times lower than those of
ciprofloxacin in the present study and those of levofloxacin in
a previous study that used the same methodology (10). All
these results indicate the potential usefulness of gemifloxacin
against infections caused by L. monocytogenes.
The activities of gemifloxacin, ciprofloxacin, ampicillin, and
gentamicin against coryneform bacteria were related to the
species. Most C. jeikeium and C. urealyticum strains were mul-
tidrug-resistant organisms that were not inhibited by ampicil-
lin, gentamicin, or ciprofloxacin. Although the percentages
of inhibition of these two species were similar for gemifloxa-
cin (12.5% of C. jeikeium strains and 10% of C. urealyticum
strains) and ciprofloxacin (10% of strains of both species)
when both drugs were used at a concentration of 0.5 mg/ml,
gemifloxacin was more active than ciprofloxacin against these
two corynebacteria, which is reflected in the lower MIC50s
(4 versus .16 mg/ml for both species) and higher percentages
of inhibition at 2 mg/ml (28 to 38% for gemifloxacin versus
10% for ciprofloxacin against both species). C. striatum was
more susceptible to gemifloxacin than to ciprofloxacin: 98, 68,
and 20% of the strains tested were inhibited by 4, 2, and 0.5 mg
of gemifloxacin per ml, respectively, whereas the rates for
ciprofloxacin were 15, 12, and 5%, respectively. Gemifloxacin
was also more active than ciprofloxacin against C. amycolatum
(58 and 32% of the strains were inhibited by the two drugs at
2 mg/ml, respectively, and 43 and 25% were inhibited by the
two drugs at 0.5 mg/ml, respectively). Gentamicin and cipro-
TABLE 1. Ranges, MIC50s, and MIC90s of antimicrobial agents
for Listeria monocytogenes and coryneform bacteria





Gemifloxacin #0.008–.16 2 16
Ciprofloxacin #0.015–.16 .16 .16
Ampicillin #0.06–.128 1 .128
Doxycycline #0.06–.128 0.125 4
Gentamicin #0.06–.128 8 .128
Vancomycin 0.125–2 0.5 0.5
L. monocytogenes (15)
Gemifloxacin 0.06–0.25 0.125 0.125
Ciprofloxacin 0.5–2 1 2
Ampicillin 0.125–1 0.5 1
Doxycycline 0.125–1 0.25 0.25
Gentamicin 0.125–2 1 1
Vancomycin 1–2 1 1
Brevibacterium spp. (15)
Gemifloxacin #0.008–2 0.06 0.125
Ciprofloxacin 0.03–.16 1 2
Ampicillin #0.06–0.5 #0.06 0.5
Doxycycline #0.06–0.25 #0.06 0.25
Gentamicin #0.06–128 0.25 2
Vancomycin 0.125–0.5 0.25 0.5
C. amycolatum (40)
Gemifloxacin #0.008–.16 1 16
Ciprofloxacin 0.015–.16 16 .16
Ampicillin #0.06–4 0.125 1
Doxycycline #0.06–4 #0.06 0.5
Gentamicin #0.06–.128 #0.06 128
Vancomycin 0.25–1 0.25 0.5
C. jeikeium (40)
Gemifloxacin #0.008–16 4 16
Ciprofloxacin 0.125–.16 .16 .16
Ampicillin 0.5–.128 .128 .128
Doxycycline 0.06–4 0.125 4
Gentamicin #0.06–.128 .128 .128
Vancomycin 0.125–0.5 0.5 0.5
C. minutissimum (20)
Gemifloxacin #0.008–4 0.015 0.5
Ciprofloxacin 0.03–.16 0.125 16
Ampicillin #0.06–1 0.5 1
Doxycycline #0.06–16 0.25 0.5
Gentamicin #0.06–4 #0.06 1
Vancomycin 0.25–0.5 0.25 0.5
C. pseudodiphteriticum (10)
Gemifloxacin #0.008–0.125 #0.008 0.03
Ciprofloxacin 0.015–2 #0.06 1
Ampicillin #0.06–0.5 #0.06 #0.06
Doxycycline #0.06–0.5 #0.06 0.25
Gentamicin #0.06 0.25 #0.06
Vancomycin 0.25–0.5 0.25 0.25
C. striatum (40)
Gemifloxacin 0.015–.16 2 4
Ciprofloxacin 0.06–.16 .16 .16
Ampicillin 0.25–4 1 4
Doxycycline 0.06–16 0.125 16
Gentamicin #0.06–.128 128 .128
Vancomycin 0.25–0.5 0.25 0.5
C. urealyticum (40)
Gemifloxacin #0.008–.16 4 .16
Ciprofloxacin 0.03–.16 .16 .16
Ampicillin #0.06–.128 .128 .128
Doxycycline 0.125–.128 0.25 4
Gentamicin #0.06–.128 .128 .128
Vancomycin 0.25–0.5 0.5 0.5
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floxacin exhibited low levels of activity against C. striatum and
C. amycolatum. The results of the present study suggest that
the susceptibility of C. striatum to the various antimicrobial
agents evaluated has decreased over the last few years. In a
previous study by our group in which we evaluated 86 strains
of C. striatum isolated during the period from 1991 to 1994,
MIC50s and MIC90s of 1 and 128 mg/ml and 4 and 16 mg/ml for
gentamicin and ciprofloxacin, respectively, were obtained, val-
ues much lower than those obtained in the present study. The
decreased activity of ciprofloxacin against other Corynebacte-
rium species (C. amycolatum, C. jeikeium, C. minutissimum,
C. urealyticum) may also be inferred when data obtained in the
present study are compared to data from previous studies
conducted by our group (10, 11). For all the strains mentioned
above, the MIC50s of ciprofloxacin have increased from 4 to
.8 times, whereas the proportions of strains inhibited by cip-
rofloxacin at 2 mg/ml have decreased from 50 to 32% (C. amy-
colatum), 50 to 10% (C. jeikeium), 87 to 75% (C. minutissi-
mum), and 44 to 10% (C. urealyticum). Other investigators have
also previously noticed the increased level of resistance of
C. urealyticum to fluoroquinolones over time (18). When data
from the present study are compared with those from a previ-
ous one (10), it may be concluded that gemifloxacin is more
active than levofloxacin against C. minutissimum and shows
activity similar to that of levofloxacin against other Corynebac-
terium species; in terms of absolute MIC50s and MIC90s, gemi-
floxacin exhibited slightly better activity than levofloxacin against
C. amycolatum and C. jeikeium and was slightly less active
against C. striatum.
Interestingly, the MIC50s and MIC90s of ampicillin for
C. amycolatum in the present study were lower than those
for C. striatum (Table 1). Previous reports have shown that
C. amycolatum was more often resistant to ampicillin than
C. striatum, a trait that could be exploited to help in the routine
identification of both organisms in the clinical laboratory (12).
This might be related to the decreased activity of ampicillin
against recent isolates of C. striatum.
Gemifloxacin was more active than ciprofloxacin against
C. minutissimum and C. pseudodiphteriticum: 90 and 100% ver-
sus 75 and 80% of C. minutissimum and C. pseudodiphteriticum
strains were inhibited by gemifloxacin and ciprofloxacin at 0.5
mg/ml, respectively. Similarly, 94 and 27% of Brevibacterium
spp. were inhibited by 0.125 mg of gemifloxacin and ciprofloxa-
cin per ml, respectively.
Few reports have investigated the mechanisms of resistance
of coryneform bacteria to antimicrobial agents. Detailed stud-
ies are required to understand the biochemical and genetic
bases of the increased levels of resistance observed in the
present study.
This study was supported by a grant from SmithKline Beecham
Pharmaceuticals.
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